Dr. Gidi Shani received his Ph.D. in cellular biology in 2004 from the laboratory of Prof. Adi Kimchi at the Weizmann Institute of Technology. His research focused on cancer biology, receptor kinases, apoptosis, protein purification, antibodies development and phosphorylation site mapping. Previously, he attended the Hebrew University of Jerusalem, where he completed his B.Sc. in life science and his MBA in finance and marketing. Dr. Shani later did post-doctoral study at the Salk institute, in the lab of Wylie Vale, where he discovered a novel protein-protein interaction specific to the membrane of cancer cells, which regulates Src, Akt and Erk activity. Upon returning to Israel, Dr. Shani became the chief scientist of BT9, a start-up company located in the Western Galilee. Dr. Shani is currently in charge of the translational research from VOC research to the development of industrial products.